<?xml version="1.0" encoding="Windows-31J"?>
<ArticleSet xmlns="http://www.openarchives.org/OAI/2.0/">
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>63</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer</ArticleTitle>
    <FirstPage LZero="delete">1261</FirstPage>
    <LastPage>1267</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takaaki</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masataka</FirstName>
        <LastName>Taoka</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Makimoto</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisao</FirstName>
        <LastName>Higo</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Tabata</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A 55-year-old man with stage IV lung adenocarcinoma was treated with cisplatin, pemetrexed, nivolumab, and ipilimumab. Approximately 100 days after treatment initiation, he became disoriented and presented to the emergency department with a high fever. Blood tests revealed liver and kidney dysfunctions. Subsequently, the patient developed generalized convulsions that required intensive care. He was clinically diagnosed with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Organ damage was gradually controlled with immunosuppressive drugs, including steroids, and the patient was discharged. Successful treatment is rare in patients with CRS, including ICANS, during immune checkpoint inhibitor treatment for solid tumors.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">immune checkpoint inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nivolumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ipilimumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cytokine release syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immune effector cell-associated neurotoxicity syndrome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
</ArticleSet>
